<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428245</url>
  </required_header>
  <id_info>
    <org_study_id>14100</org_study_id>
    <secondary_id>U54HD028934</secondary_id>
    <secondary_id>P50HD028934</secondary_id>
    <nct_id>NCT01428245</nct_id>
  </id_info>
  <brief_title>Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition</brief_title>
  <acronym>JCM026</acronym>
  <official_title>Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition in Early Pubertal Girls (JCM026)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gonadotropin-releasing hormone (GnRH) is a hormone that regulates the ability of the&#xD;
      pituitary to secrete two hormones, luteinizing hormone (LH) and follicle-stimulating hormone&#xD;
      (FSH). LH and FSH control the production of female hormones (such as estrogen and&#xD;
      progesterone) and the development of eggs by the ovary. Progesterone and estrogen then&#xD;
      decrease the number of GnRH pulses produced by the brain (and therefore the number of LH&#xD;
      pulses from the pituitary). The ability to decrease GnRH pulses seems to be very important&#xD;
      for normal menstrual function in adult women. The purpose of this study is to learn more&#xD;
      about how GnRH and LH pulses are controlled during puberty. The information gathered in this&#xD;
      study will hopefully allow us to learn more about how menstrual cycles are normally&#xD;
      established in girls during puberty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will aim to discover the effect of 7 days of estrogen and&#xD;
      progesterone on GnRH pulses in girls in early and mid puberty. Ultimately, if the&#xD;
      investigators understand these normal processes, the investigators may be able to better&#xD;
      understand abnormalities of puberty.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The research questions was changed/de-prioritized. Only one subject completed.&#xD;
  </why_stopped>
  <start_date type="Actual">April 22, 2011</start_date>
  <completion_date type="Actual">May 14, 2013</completion_date>
  <primary_completion_date type="Actual">May 14, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LH Pulse Frequency as a Function of Day 7 Progesterone</measure>
    <time_frame>7 days following oral estrace and progesterone administration</time_frame>
    <description>number of LH pulses per 11 hours on Day 7 of progesterone</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hyperandrogenemia</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Progesterone, estrace</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days&#xD;
oral estrace, 0.5-1 mg once a day for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days</description>
    <arm_group_label>Progesterone, estrace</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrace (estrogen)</intervention_name>
    <description>oral estrace, 0.5-1 mg once a day for seven days</description>
    <arm_group_label>Progesterone, estrace</arm_group_label>
    <other_name>estradiol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Girls ages 8 to 14&#xD;
&#xD;
          -  Tanner 1-3 pubertal stage&#xD;
&#xD;
          -  Pre-menarchal&#xD;
&#xD;
          -  Normal screening labs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal screening labs&#xD;
&#xD;
          -  Congenital adrenal hyperplasia&#xD;
&#xD;
          -  Hyperandrogenism (e.g., hirsutism, elevated free testosterone level)&#xD;
&#xD;
          -  Hemoglobin &lt;12 mg/dL or hematocrit &lt; 36% (Subjects will be offered the opportunity to&#xD;
             take iron supplementation for 60 days if their hematocrit is slightly low (33-36%)&#xD;
             (suggestive of iron deficiency anemia) and will then return for retesting of their&#xD;
             hemoglobin/hematocrit.)&#xD;
&#xD;
          -  Weight &lt; 31 kg&#xD;
&#xD;
          -  History of peanut allergy, deep venous thrombosis, breast cancer, endometrial cancer,&#xD;
             or cervical cancer&#xD;
&#xD;
          -  On hormonal medications (including oral contraceptive pills) or on medications known&#xD;
             to affect the reproductive axis within 3 months of the study&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Participation in a research study within the past 30 days that involved taking a study&#xD;
             drug.&#xD;
&#xD;
          -  Participation in a research study that involved taking up to or greater than 473 ml's&#xD;
             of blood within the past 60 days.&#xD;
&#xD;
          -  Cigarette smoking&#xD;
&#xD;
          -  History of surgery that required bedrest within the past 30 days&#xD;
&#xD;
          -  Family history of hypercoagulability or unexplained thromboembolic disease (not in&#xD;
             setting of bedrest, surgery, or malignancy)&#xD;
&#xD;
          -  In order to ensure an adequate number of younger girls, no more than 4 enrolled&#xD;
             subjects will be Tanner stage 3&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C. Marshall, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Research in Reproduction, University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>September 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2011</study_first_posted>
  <results_first_submitted>November 10, 2020</results_first_submitted>
  <results_first_submitted_qc>December 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 30, 2020</results_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>John Marshall</investigator_full_name>
    <investigator_title>Director, Center for Research in Reproduction</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 29, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT01428245/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT01428245/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 subjects enrolled in this study. 2 subjects completed screening procedures only (these 2 subjects were withdrawn from study prior to being assigned to an arm of intervention).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Progesterone, Estrace</title>
          <description>oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days&#xD;
oral estrace, 0.5-1 mg once a day for seven days&#xD;
Progesterone: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days&#xD;
Estrace (estrogen): oral estrace, 0.5-1 mg once a day for seven days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Progesterone, Estrace</title>
          <description>oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days&#xD;
oral estrace, 0.5-1 mg once a day for seven days&#xD;
Progesterone: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days&#xD;
Estrace (estrogen): oral estrace, 0.5-1 mg once a day for seven days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LH Pulse Frequency as a Function of Day 7 Progesterone</title>
        <description>number of LH pulses per 11 hours on Day 7 of progesterone</description>
        <time_frame>7 days following oral estrace and progesterone administration</time_frame>
        <population>Only one subject completed study.</population>
        <group_list>
          <group group_id="O1">
            <title>Progesterone, Estrace</title>
            <description>oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days&#xD;
oral estrace, 0.5-1 mg once a day for seven days&#xD;
Progesterone: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days&#xD;
Estrace (estrogen): oral estrace, 0.5-1 mg once a day for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>LH Pulse Frequency as a Function of Day 7 Progesterone</title>
          <description>number of LH pulses per 11 hours on Day 7 of progesterone</description>
          <population>Only one subject completed study.</population>
          <units>number of LH pulses/11hr</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days post study drug intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Progesterone, Estrace</title>
          <description>oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days&#xD;
oral estrace, 0.5-1 mg once a day for seven days&#xD;
Progesterone: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days&#xD;
Estrace (estrogen): oral estrace, 0.5-1 mg once a day for seven days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Coordinator</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-243-6911</phone>
      <email>pcos@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

